ESR1 and breast carcinoma: While currently, selection of ET for women with advanced ER+ breast cancer is based on IHC assays of ER, PgR, and HER2, there are many emerging methods based on more extensive genomic, transcriptomic, proteomic, metabolomic, and other information-rich characterizations of biopsy samples21–23.